MedTrace Logo

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

NCT05718791 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-05-01

No results posted yet for this study

Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Conditions

  • GVHD,Acute

Interventions

DIAGNOSTIC_TEST

blood sample

blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718791 on ClinicalTrials.gov